By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new ...
Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.
The approval was supported by data from the ongoing Phase III MajesTEC-3 study.
The US Food and Drug Administration (FDA) has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for ...
MedPage Today on MSN
Myeloma combo with 'unprecedented' effect wins FDA approval
In second- or later-line setting, combination cut risk of disease progression or death by ...
March 5 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Johnson & Johnson's treatment for a type of ...
The FDA is expected to decide on treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity.
Ascendis Pharma A/S shares are up during Monday’s premarket session following the FDA’s approval of Yuviwel (navepegritide; ...
The FDA has approved the first combination, targeted regimen for previously untreated BRAF V600E mutation-positive metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, ...
On Friday, the U.S. Food and Drug Administration (FDA) approved BioMarin Pharmaceutical Inc.’s supplemental application for ...
Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results